Push­ing hard for block­buster re­turns, No­var­tis finds PhI­II da­ta to as­sert Mayzent boosts cog­ni­tive pow­ers in MS pa­tients

A hard-charg­ing group of No­var­tis ex­ecs have been pour­ing over the late-stage da­ta they gath­ered to sup­port their suc­cess­ful cam­paign to win an FDA ap­proval for Mayzent (sipon­i­mod) as a land­mark new ther­a­py for mul­ti­ple scle­ro­sis. And it’s paid off

Crunch­ing the da­ta on their MS drug — tapped as a $1.3 bil­lion block­buster-in-the-mak­ing by Eval­u­ate — re­searchers con­clud­ed that there was clear sta­tis­ti­cal ev­i­dence to show that their drug both pre­served the cog­ni­tive pow­ers of sec­ondary pro­gres­sive MS pa­tients treat­ed ear­li­er in the course of their dis­ease as well boost­ing the abil­i­ty of pa­tients to think. Pa­tients on their drug beat a con­trol group giv­en a place­bo.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER